Clinical Trial Search

Primary: Change From Baseline in the Restless Legs Syndrome Rating Scale — -14.0000; -9.7353 units on a scale — p=0.2742

Primary: Physician's Global Assessment of Improvement — 2 score on a scale

Primary: Number of Participants With at Least One Moderate or Severe Asthma Exacerbation Over Time — 5; 4; 13; 12 Participants — p=0.32

Primary: Percent Increase in Glutathione (GSH) Concentrations in the ACC — 5; 0; 2 Percent change

Primary: [PCR Saliva] Percent Change From Baseline Ct Viral Targets — 5.8; 1.3 % Change from Baseline Cycle Threshold — p=0.287

Primary: Number of Maternal Subjects With Pregnancy Outcomes — 2088; 18; 8; 5 Participants

Primary: Improvement in GRA for Overall Bladder Symptoms — 3; 2 Participants

Primary: Number of Participants With Major Adverse Events (MAE) — 0 Participants

Primary: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 9077.08; 951.58 hour * nanomole / liter

Primary: Incidence of Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants

Primary: Colorectal Cancer Screening Rate — 333; 162 Participants

Primary: Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6 — -0.1; -2.3; -3.7 units on a scale — p=<0.001

Primary: Change in PCL-M Score From Baseline to 12 Days — -12.88 score on a scale

Primary: Percent of Subjects' Study Eyes With Pupil Diameter Returning to Baseline — 46; 6 Participants

Primary: Placebo-corrected Change From Baseline For QTcF (ΔΔQTcF) for ALXN1840 Using The By-time Point Analysis — -0.21; -0.31; 0.07; -0.64 ms